The resorbable cryoprobe device and process is a novel approach for treating localized
disease allowing for the precise combined application of freezing temperatures and cytotoxic or cryosensitizing agents within a self-contained matrix /
package for optimized tissue destruction. The cryopellet is comprised of a
list of components including a source of cryogen to produce the sub-zero temperatures, a porous matrix to contain the cytotoxic agent, cytotoxic agent, and a delivery packet. Data presented herein demonstrates the
efficacy of this approach in destroying cancerous tissue. For example, the application of freezing temperatures to −10° C. results in approximately 15%
cell death, while
exposure to cytotoxic agents such as TRAIL produces minimal
cell death. The utilization of the cryopellet approach results in a synergistic effect yielding complete
cell death at the same temperature. The innovation behind the resorbable probe application includes the strategic combination of agents to activate intrinsic or extrinsic cell death responses (including
apoptosis and
necrosis), unique packaging of the cryogen and cytotoxic agent, and a unique
delivery system. The resorbable cryoprobe technology will assist directly in the treatment of
cancer, as well as will likely lead to broader application for
disease treatment.